182 related articles for article (PubMed ID: 34393062)
21. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
22. Tumor immunity is related to
Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
[TBL] [Abstract][Full Text] [Related]
23. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
Serpico D; Trama A; Haspinger ER; Agustoni F; Botta L; Berardi R; Palmieri G; Zucali P; Gallucci R; Broggini M; Gatta G; Pastorino U; Pelosi G; de Braud F; Garassino MC
Ann Oncol; 2015 May; 26(5):838-847. PubMed ID: 25411417
[TBL] [Abstract][Full Text] [Related]
24. Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors.
Valdivia D; Cheufou D; Fels B; Puhlvers S; Mardanzai K; Zaatar M; Weinreich G; Taube C; Theegarten D; Stuschke M; Schuler M; Stamatis G; Hegedus B; Aigner C
Pathol Oncol Res; 2021; 27():629993. PubMed ID: 34257595
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the effectiveness of chemotherapy for thymic epithelial tumors using the CD-DST method.
Yu L; Zhang BX; Du X; Yu Z; Yang XG; Jiang YX
Thorac Cancer; 2020 May; 11(5):1160-1169. PubMed ID: 32196982
[TBL] [Abstract][Full Text] [Related]
26. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
27. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Chen Y; Zhang Y; Chai X; Gao J; Chen G; Zhang W; Zhang Y
Biomed Res Int; 2018; 2018():5830547. PubMed ID: 29850538
[TBL] [Abstract][Full Text] [Related]
28. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
[TBL] [Abstract][Full Text] [Related]
29. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
Hann CL; Scherpereel A; Hellyer JA; Wakelee HA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():543-552. PubMed ID: 31099677
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
Yamamoto Y; Iwahori K; Funaki S; Matsumoto M; Hirata M; Yoshida T; Kanzaki R; Kanou T; Ose N; Minami M; Sato E; Kumanogoh A; Shintani Y; Okumura M; Wada H
Sci Rep; 2020 Mar; 10(1):4064. PubMed ID: 32132638
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis in thymic epithelial tumors.
Park SH; Kim HK; Kim H; Ro JY
Pathol Res Pract; 2002; 198(7):461-7. PubMed ID: 12234065
[TBL] [Abstract][Full Text] [Related]
32. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors.
Umemura S; Zhu J; Chahine JJ; Kallakury B; Chen V; Kim IK; Zhang YW; Goto K; He Y; Giaccone G
Lung Cancer; 2020 Sep; 147():221-228. PubMed ID: 32738418
[TBL] [Abstract][Full Text] [Related]
34. Construction of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in thymic epithelial tumors.
Su Y; Ou Y; Chen Y; Ma X
Biosci Rep; 2022 May; 42(5):. PubMed ID: 35438133
[TBL] [Abstract][Full Text] [Related]
35. Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors.
Janik S; Bekos C; Hacker P; Raunegger T; Schiefer AI; Müllauer L; Veraar C; Dome B; Klepetko W; Ankersmit HJ; Moser B
Sci Rep; 2019 Nov; 9(1):17359. PubMed ID: 31757999
[TBL] [Abstract][Full Text] [Related]
36. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Petrini I; Meltzer PS; Zucali PA; Luo J; Lee C; Santoro A; Lee HS; Killian KJ; Wang Y; Tsokos M; Roncalli M; Steinberg SM; Wang Y; Giaccone G
Cell Death Dis; 2012 Jul; 3(7):e351. PubMed ID: 22825469
[TBL] [Abstract][Full Text] [Related]
37. Growth of thymic epithelial tumors and thymic cysts: Differential radiological points.
Kim H; Yoon SH; Kim J; Lee KW; Choi YR; Cho H; Goo JM
Thorac Cancer; 2019 Apr; 10(4):864-871. PubMed ID: 30793538
[TBL] [Abstract][Full Text] [Related]
38. Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study.
Shen W; Jin Y; Yu Y; Chen N; Fan Y
Thorac Cancer; 2024 Jan; 15(2):122-130. PubMed ID: 38011005
[TBL] [Abstract][Full Text] [Related]
39. Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.
Ocak S; Friedman DB; Chen H; Ausborn JA; Hassanein M; Detry B; Weynand B; Aboubakar F; Pilette C; Sibille Y; Massion PP
J Thorac Oncol; 2014 Mar; 9(3):324-36. PubMed ID: 24518087
[TBL] [Abstract][Full Text] [Related]
40. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
